Provided by Tiger Trade Technology Pte. Ltd.

Nice Ltd

111.37
-0.4900-0.44%
Post-market: 113.001.63+1.46%16:35 EST
Volume:797.47K
Turnover:88.44M
Market Cap:6.88B
PE:12.68
High:112.49
Open:111.68
Low:108.85
Close:111.86
52wk High:180.61
52wk Low:99.00
Shares:61.74M
Float Shares:61.40M
Volume Ratio:0.75
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.79
EPS(LYR):6.76
ROE:15.08%
ROA:7.62%
PB:1.78
PE(LYR):16.47

Loading ...

Press Release: NiCE Provides Webcast and Dial-in Details for its Fourth Quarter 2025 Results Teleconference

Dow Jones
·
Feb 05

8 Software Stocks to Buy That Are Actually Profitable -- and Cheap -- Barrons.com

Dow Jones
·
Feb 04

These software stocks could rise as much as 75%. But is now the time to buy?

Dow Jones
·
Feb 03

NiCE Launches AI Performance Lab for Enterprise-Scale Agent Evaluations

MT Newswires Live
·
Jan 20

NICE Is Maintained at Buy by Rosenblatt

Dow Jones
·
Dec 23, 2025

Intel, Adobe and these other 'AI loser' stocks could get left behind in the next phase of the tech boom

Dow Jones
·
Dec 08, 2025

NICE Cut to Neutral From Outperform by Wedbush

Dow Jones
·
Dec 08, 2025

Nice Ltd : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $120 From $170

THOMSON REUTERS
·
Dec 08, 2025

Wedbush Downgrades NICE to Neutral From Outperform, Cuts Price Target to $120 From $170

MT Newswires Live
·
Dec 08, 2025

Britain is missing out on pharma investment thanks to medicine rationing

cityam
·
Dec 03, 2025

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

Benzinga_recent_news
·
Nov 26, 2025

Autolus Therapeutics announces NICE draft guidance recommending Aucatzyl

TIPRANKS
·
Nov 25, 2025

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

GlobeNewswire
·
Nov 25, 2025

Congressman Buys Shares Of Small AI Company You've Probably Never Heard Of

Benzinga_recent_news
·
Nov 20, 2025

Stock Track | Nice Ltd Plummets 5.06% After Barclays Slashes Price Target

Stock Track
·
Nov 20, 2025

Stock Track | Nice Ltd Plummets 5.06% as Barclays Slashes Price Target

Stock Track
·
Nov 20, 2025

Nice price target lowered to $165 from $200 at Barclays

TIPRANKS
·
Nov 19, 2025

Barclays Reaffirms Their Buy Rating on NICE (NICE)

TIPRANKS
·
Nov 19, 2025

NICE Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Nov 19, 2025

Nice's Substantial Near-Term Investments Need to Lead to Revenue Acceleration, Morgan Stanley Says

MT Newswires Live
·
Nov 19, 2025